Abstract
Following five previous biennial surveys, this 1992 study analyzed renal cell carcinoma (RCC) cases diagnosed over a two-year period across 1,435 Japanese dialysis centers. The survey identified 184 cases, the highest number reported to date. The average patient age was 53.8 years, with a mean dialysis duration of 111 months. Notably, nearly half of the patients (48.6%) had been on dialysis for over 10 years. Most cases were asymptomatic and detected via screening (ultrasound or CT). Acquired cystic disease of the kidney (ARCD) was present in 79.2% of cases. While the incidence of RCC was four times higher in patients with over 10 years of dialysis compared to those with shorter durations, the presence of ARCD did not significantly correlate with higher metastatic rates. These findings emphasize the critical need for regular screening in long-term dialysis populations.
Introduction
By the early 1990s, advancements in hemodialysis significantly extended the life expectancy of patients with chronic kidney failure. However, this longevity revealed a troubling trend: a rising incidence of renal cell carcinoma (RCC) far exceeding that of the general population. This study sought to quantify this risk and identify key clinical markers, specifically investigating the role of dialysis duration and Acquired Renal Cystic Disease (ARCD) in tumor development.
Methods
In February 1992, researchers conducted a nationwide questionnaire-based study targeting 2,283 dialysis units in Japan. With a 64.1% response rate, the study captured data on 184 newly diagnosed RCC cases between March 1990 and February 1992. Statistical analyses, including T-tests and Chi-square tests, were employed to compare patient subgroups, while historical data from previous surveys (1982–1990) and the Osaka Cancer Registry provided longitudinal and population-level context.
Key Insights and Results
The 10-Year Risk Threshold
The most significant finding was the correlation between dialysis duration and cancer risk. The annual incidence rate for patients on dialysis for more than 10 years was 310 per 100,000—approximately four times higher than the rate for those treated for less than a decade (77 per 100,000).
The Silent Nature of Dialysis-Related RCC
Clinical symptoms were rare, appearing in only 7.6% of patients. The vast majority of cases were identified through proactive screening: 93 via ultrasound and 71 via CT scan. This underscores that by the time symptoms manifest in a dialysis patient, the malignancy may already be advanced.
ARCD and Gender Disparity
Acquired Renal Cystic Disease (ARCD) was a prevalent comorbidity, found in nearly 80% of the RCC patients. The data confirmed that longer dialysis duration increases the likelihood of ARCD, which subsequently serves as a precursor for malignant transformation. Additionally, a marked gender disparity was observed; men were 4.4 times more likely than women to develop RCC, a ratio significantly higher than that found in the general Japanese population at the time.
Clinical Outcomes and Metastasis
The mean tumor diameter was 4.7 cm. While tumors associated with ARCD were often caught earlier due to closer monitoring, they were not necessarily less aggressive. Metastasis was present in 15.9% of cases at the time of diagnosis.
Curative nephrectomy remained the primary intervention, with 124 out of 182 patients (68.1%) reported as alive and tumor-free following surgery.
Conclusion
The 1992 survey highlights a clear escalation in RCC incidence among the dialysis population, driven largely by the growing cohort of long-term survivors. As patients cross the 10-year treatment milestone, the risk of "silent" tumors increases four-fold. These results advocate for standardized, frequent imaging protocols—specifically ultrasound and CT—to ensure early detection and improve survival outcomes in this high-risk group.
Summary updated